Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board

AUA publishes list of tests and treatments to question as part of “Choosing Wisely”

June 01, 2017
Vol.40 No.05

Active surveillance preserves quality of life for prostate cancer patients, Vanderbilt study concludes

May 01, 2017
Vol.40 No.04

In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

March 30, 2017
Vol.40 No.03

Regimen Extends Life for Some Men With Recurrent Prostate Cancer

February 28, 2017
Vol.40 No.02

Study Shows Only Nuclear-Localized AR-V7 Predictive of Benefit for Patients with Metastatic Disease

January 25, 2017
Vol.40 No.01

Axumin Detects 68% of Recurrent Prostate Cancer in Phase III Study

November 29, 2016
Vol.39 No.10

Custirsen Trial Fails to Show Improvement in Survival

September 22, 2016
Vol.39 No.08

Study: SBRT Delivers 98.6% Cure Rate at Five-Year Followup

May 02, 2016
Vol.- No.-
FreeTCCL Archive

Galeterone Shows Potential in CRPC AR Variants, Study Says

December 01, 2014
Vol.37 No.11
FreeTCCL Archive

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

October 30, 2014
Vol.37 No.10

Posts navigation

Previous1…141516Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
  • FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
    Draft guidance consolidates trial design updates for developers
  • Trump imposes up to 100% tariff on some brand name pharmaceutical companies
  • Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account